11 results on '"Karl Ulrich Petry"'
Search Results
2. German evidence and consensus‐based (S3) guideline: Vaccination recommendations for the prevention of HPV‐associated lesions
- Author
-
Ralf Köllges, Gerd Gross, Martin Schlaeger, Jens Peter Klußmann, Sven Tiews, Hans-Jürgen Laws, Peter Hillemanns, Klaus J. Neis, Julia Gallwas, Peter Schneede, Klaus Doubek, Norbert H. Brockmeyer, Markus Bickel, Matthew Gaskins, Rafael T. Mikolajczyk, Karl Ulrich Petry, Ulrike Wieland, Gabriela L. Avila Valle, Heidemarie Haase, Markus Knuf, Johannes Jongen, Hans Ikenberg, Andreas M. Kaufmann, Herbert Pfister, Alexander Nast, Achim Schneider, Sigrun Smola, Magnus von Knebel Doeberitz, Friederike Gieseking, and Ricardo Niklas Werner
- Subjects
medicine.medical_specialty ,Consensus ,MEDLINE ,Dermatology ,Disease ,German ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Quality of life (healthcare) ,Health care ,medicine ,Humans ,Papillomaviridae ,business.industry ,Papillomavirus Infections ,Vaccination ,Guideline ,language.human_language ,3. Good health ,Immunization ,030220 oncology & carcinogenesis ,Family medicine ,Quality of Life ,language ,business - Abstract
Anogenital and oropharyngeal infections with human papilloma viruses (HPV) are common. Clinically manifest disease may significantly impact quality of life; the treatment of HPV-associated lesions is associated with a high rate of recurrence and invasive neoplasms, such as cervical, anal, vulvar, penile, and oropharyngeal cancers, which are characterized by significant morbidity and mortality. Vaccination against HPV is an effective and safe measure for the primary prevention of HPV-associated lesions, but immunization rates are still low in Germany. The present publication is an abridged version of the German evidence and consensus-based guideline "Vaccination recommendations for the prevention of HPV-associated lesions", which is available on the website of the German Association of the Scientific Medical Societies (AWMF). On the basis of a systematic review with meta-analyses, a representative panel developed and agreed upon recommendations for the vaccination of different populations against HPV. In addition, consensus-based recommendations were developed for specific issues relevant to everyday practice. Based on current evidence and a representative expert consensus, these recommendations are intended to provide guidance in a field in which there is often uncertainty and in which both patients and health care providers are sometimes confronted with controversial and emotionally charged points of view.
- Published
- 2021
- Full Text
- View/download PDF
3. Evaluating HPV‐negative CIN2+ in the ATHENA trial
- Author
-
Wim Quint, Mario Sideri, Karl Ulrich Petry, Catherine M. Behrens, J. Thomas Cox, R. Ridder, Thomas C. Wright, and Kristin Johnson
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,HPV genotype ,education ,cervical cancer screening ,Uterine Cervical Neoplasms ,cervical intraepithelial neoplasia ,Cervical cancer screening ,Cervical intraepithelial neoplasia ,histology ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,adenocarcinoma in situ ,HPV Negative ,Internal medicine ,Post-hoc analysis ,Humans ,Mass Screening ,Medicine ,Clinical significance ,Early Detection of Cancer ,Mass screening ,Gynecology ,biology ,Hpv types ,business.industry ,Papillomavirus Infections ,HPV DNA testing ,Uterine Cervical Dysplasia ,medicine.disease ,biology.organism_classification ,Acis ,United States ,female genital diseases and pregnancy complications ,Infectious Causes of Cancer ,030104 developmental biology ,030220 oncology & carcinogenesis ,Female ,Neoplasm Grading ,business - Abstract
A post hoc analysis of the ATHENA study was performed to determine whether true HPV‐negative cervical lesions occur and whether they have clinical relevance. The ATHENA database was searched for all CIN2 or worse (CIN2+) cases with cobas HPV‐negative results and comparison was made with Linear Array (LA) and Amplicor to detect true false‐negative HPV results. Immunostaining with p16 was performed on these cases to identify false‐positive histology results. H&E slides were re‐reviewed by the study pathologists with knowledge of patient age, HPV test results and p16 immunostaining. Those with positive p16 immunostaining and/or a positive histopathology review underwent whole tissue section HPV PCR by the SPF10/LiPA/RHA system. Among 46,887 eligible women, 497 cases of CIN2+ were detected, 55 of which tested negative by the cobas® HPV Test (32 CIN2, 23 CIN3/ACIS). By LA and/or Amplicor, 32 CIN2+ (20 CIN2, 12 CIN3/ACIS) were HPV positive and categorized as false‐negatives by cobas HPV; nine of 12 false‐negative CIN3/ACIS cases were p16+. There were 23 cases (12 CIN2, 11 CIN3/ACIS) negative by all HPV tests; seven of 11 CIN3/ACIS cases were p16+. H&E slides were available for six cases for re‐review and all were confirmed as CIN3/ACIS. Tissue PCR was performed on the six confirmed CIN3/ACIS cases (and one without confirmation): four were positive for HPV types not considered oncogenic, two were positive for oncogenic genotypes and one was indeterminate. In summary, subanalysis of a large cervical cancer screening study did not identify any true CIN3/ACIS not attributable to HPV., What's new? Human papillomavirus (HPV) testing has a high negative predictive value for detecting histological cervical intraepithelial neoplasia (CIN). False‐negative HPV results can occur, however, though their clinical relevance is little understood. Using data from the U.S.‐based ATHENA study, the authors of the present report show that only a very small percentage of CIN grade 3/adenocarcinoma in situ (ACIS) lesions were missed by the cobas HPV Test, which identifies 14 high‐risk HPV types. False‐negatives by cobas testing were compared with Linear Array and Amplicor testing. Most missed CIN3/ACIS cases were associated with HPV types not included in current tests.
- Published
- 2016
- Full Text
- View/download PDF
4. Efficacy and safety of hexaminolevulinate photodynamic therapy in patients with low-grade cervical intraepithelial neoplasia
- Author
-
Pierre Collinet, Alexander Luyten, Karl Ulrich Petry, Philipp Soergel, Julia Gallwas, Peter Hillemanns, Katty Ardaens, and Christian Dannecker
- Subjects
Cervical cancer ,Colposcopy ,medicine.medical_specialty ,education.field_of_study ,Low Grade Cervical Intraepithelial Neoplasia ,medicine.diagnostic_test ,business.industry ,Population ,Dermatology ,Cervical intraepithelial neoplasia ,medicine.disease ,Placebo ,Gastroenterology ,Surgery ,Internal medicine ,Biopsy ,Medicine ,business ,education ,Adverse effect - Abstract
Objective Non-surgical therapies are needed to reduce the rate of progression of low-grade cervical intraepithelial neoplasia (CIN 1) to high grade CIN (CIN 2/3). The aim of this study was to assess the efficacy and safety of hexaminolevulinate (HAL) photodynamic therapy (PDT) in the treatment of patients with CIN 1. Study Design This phase IIa prospective double-blind study randomized patients with CIN 1 into three groups: HAL vaginal suppository, placebo vaginal suppository or follow-up only. Patients in the first two groups received HAL or placebo suppositories 5 hours before illumination with 50 J/cm2 red coherent light (633 nm) using a special light catheter. All patients had a follow up including colposcopy, cytology and human papilloma virus (HPV) testing 3 and 6 months and additional biopsy 6 months after PDT. The main outcome measure was efficacy, defined as complete histologic remission 6 months after PDT. Secondary outcomes were histologic remission 3 months and HPV eradication 6 months after first PDT. Results Seventy patients were randomized: 47 to HAL, 12 to placebo, 11 to follow up only. After 6 months CIN lesions had cleared in 57% of patients in the HAL-PDT group compared to 25% in the combined control group (per protocol population, P = 0.04). Twenty-six patients (37%) reported 44 adverse events (AEs), of which 40 were mild or moderate. Nineteen treatment-related AEs were reported by 15 patients (32%) in the HAL PDT group, one in the placebo PDT group (8%), and none in the follow-up group. The most common adverse events were local discomfort including mild pain/cramping (11) and leucorrhoea (2). Conclusion HAL PDT shows a favorable efficacy and safety profile and represents a promising alternative to observation and surgical procedures in patients with CIN 1. Lasers Surg. Med. 46:456–461, 2014. © 2014 Wiley Periodicals, Inc.
- Published
- 2014
- Full Text
- View/download PDF
5. Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme
- Author
-
Nina Buttmann-Schweiger, Karl Ulrich Petry, Martina Pietralla, Alexander Luyten, Axel Reinecke-Lüthge, Claudia Mauritz, Chris J.L.M. Meijer, and K Luyten
- Subjects
Gynecology ,Colposcopy ,Cervical cancer ,Cancer Research ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Obstetrics ,Incidence (epidemiology) ,HPV infection ,Cancer ,medicine.disease ,Cervical intraepithelial neoplasia ,female genital diseases and pregnancy complications ,Confidence interval ,Exact test ,Oncology ,medicine ,business - Abstract
We evaluated compliance with human papillomavirus (HPV) testing and risk-adapted patient pathways and monitored changes in high-grade cervical disease during long-term follow-up. Women aged >30 years attending routine screening for cervical cancer were managed according to results from first-round screening tests (cytology and high-risk HPV; Hybrid Capture 2). Between February 2006 and January 2011, 19,795 of 19,947 women agreed to participate, of whom 4,067 proceeded to a second screening round 5 years after recruitment. Predefined endpoints were compliance, grade 3 cervical intraepithelial neoplasia or cancer (CIN3+), new HPV infection, HPV persistence and abnormal smears in round 2. A total of 765 of 19,795 women (3.9%) in round 1 and 41 of 4,067 (1.0%) in round 2 were referred for colposcopy. Compliance rates with colposcopy were 93.1 and 92.7%, respectively, while histological assessment was performed in 680 of 712 (95.5%) and 36 of 38 (94.7%), respectively. CIN3+ rates were 172 of 19,795 (0.87%; 95% confidence intervals: 0.7-1.0) in round 1 and 2 of 4,064 (0.05%; 95% confidence intervals: 0.006-0.2) in round 2; the difference was statistically significant (Fisher's exact test, p
- Published
- 2014
- Full Text
- View/download PDF
6. Evaluation of the performance of the novel PapilloCheck® HPV genotyping test by comparison with two other genotyping systems and the HC2 test
- Author
-
Betti Schopp, Thomas Iftner, Manola Zago, Barbara Holz, Frank Stubenrauch, Susanne K. Kjaer, and Karl Ulrich Petry
- Subjects
Cervical cancer ,business.industry ,Concordance ,Cervical intraepithelial neoplasia ,medicine.disease ,Virology ,law.invention ,Infectious Diseases ,medicine.anatomical_structure ,law ,Genotype ,medicine ,business ,Cervix ,Genotyping ,Kappa ,Polymerase chain reaction - Abstract
The novel PapilloCheck® genotyping test was compared with SPF10 PCR LiPav1 and PGMY09/11 on hybrid capture 2 (HC2)-pretested samples. From results of 826 cervical samples detection rates and kappa values for the tests were calculated using a HPV type consensus definition. With PapilloCheck® HPV types 53, 56, and 33 were found with a sensitivity of 100%. The lowest detection rate was observed for HPV 35 (72.2%). The SPF10 PCR LiPav1 was found to be 100% positive for HPV 18, 31, 53, 56, and 35 and lowest for HPV 59 (81%). The PGMY09/11 system detected only HPV 59 at 100% detection rate and showed lowest sensitivity for HPV 56 (40.5%). Multiple infection rates ranged from 25.8% (PGMY09/11 PCR-LBA), over 39.5% (PapilloCheck®) to 55.9% (SPF10 PCR LiPav1). In samples with higher viral DNA load detection rates and concordance between the genotyping tests increases. The kappa values in comparison to the HPV consensus type ranged from k = 0.21 to k = 0.82 for comparing SPF10 PCR with the HPV consensus type, while values for PGMY09/11 PCR ranged from k = 0 to k = 0.96 and were best for the PapilloCheck® (k = 0.49–0.98). Detection rates for the identification of high-grade cervical intraepithelial neoplasia (CIN2+) ranged from 93.7% (PGMY09/11 PCR) to 98.4% (PapilloCheck®, SPF10 PCR, HC2). In conclusion, this study shows that the PapilloCheck® give comparable results to established PCR methods. However, these results also show a necessity for the standardization of genotype-specific HPV detection assays. J. Med. Virol. 82:605–615, 2010. © 2010 Wiley-Liss, Inc.
- Published
- 2010
- Full Text
- View/download PDF
7. Comparison of the performance of different HPV genotyping methods for detecting genital HPV types
- Author
-
Christian Munk, Barbara Holz, Peter J.F. Snijders, Wim Quint, Karl Ulrich Petry, Betti Schopp, Thomas Iftner, Stefanie J. Klug, Anco Molijn, Angelika Iftner, Susanne K. Kjaer, Pathology, and CCA - Innovative therapy
- Subjects
Vaginal Smears ,Genotype ,business.industry ,Papillomavirus Infections ,Consensus PCR ,Uterine Cervical Neoplasms ,Cervix Uteri ,Gold standard (test) ,Cervical intraepithelial neoplasia ,medicine.disease ,Sensitivity and Specificity ,Virology ,Infectious Diseases ,Humans ,Medicine ,Female ,Sex organ ,Typing ,business ,Papillomaviridae ,Genotyping ,Kappa - Abstract
Classification of high-risk HPV types for cervical cancer screening depends on epidemiological studies defining HPV type-specific risk. The genotyping tests that are used, are however, not uniform with regard to type-specific detection rates making comparisons between different studies difficult. To overcome the lack of a “gold standard” four tests were evaluated crosswise using 824 cervical smears pretested by HC2. The tests evaluated were the L1-PCR-based assays PGMY09/11 LBA, HPV DNA Chip and SPF LiPA and an E1 consensus PCR followed by cycle sequencing (E1-PCR). A subset of 265 samples was tested in addition with the GP5+/6+ reverse line blot assay. Differences were noted in the sensitivity and range for specific HPV types, e.g. with detection rates for HPV53 ranging from 2.3% to 11.6%. HPV16 was the most prevalent type detected by all tests except for the SPF-10 LiPa, which detected HPV31 more often. Kappa values calculated ranged from poor (k = 0.20) to intermediate (k = 0.54) for HPV positivity, but were higher for high-risk type positivity (k = 0.31–0.61) and best for recognition of HPV16 (k = 0.53–0.72). The analytical sensitivity of the tests ranged between 15% and 97% for individual types and specificity was highly dependent on which test system was used as “gold standard” for the analysis. The results of histology were used for calculation of clinical sensitivity and specificity. E1-PCR, PGMY09/11 LBA and SPF-10 LiPA had a high clinical sensitivity (>95%) for the detection of cervical intraepithelial neoplasia 2 or higher, whereas the HPV DNA Chip reached only 84.1%. J. Med. Virol. 80: 1264–1274, 2008. © 2008 Wiley-Liss, Inc.
- Published
- 2008
- Full Text
- View/download PDF
8. Overview of the European and North American studies on HPV testing in primary cervical cancer screening
- Author
-
Anne Szarewski, Shalini L Kulasingam, Karl Ulrich Petry, Christine Clavel, Chris J.L.M. Meijer, Sam Ratnam, Philippe Birembaut, Heike Hoyer, Peter Sasieni, Jack Cuzick, and Thomas Iftner
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Uterine Cervical Neoplasms ,Cervical cancer screening ,Sensitivity and Specificity ,Cytology ,medicine ,Humans ,Mass Screening ,Papillomaviridae ,Aged ,Aged, 80 and over ,Cervical cancer ,Gynecology ,Cervical screening ,Obstetrics ,business.industry ,HPV Positive ,Papillomavirus Infections ,virus diseases ,Middle Aged ,medicine.disease ,female genital diseases and pregnancy complications ,Europe ,Hpv testing ,Oncology ,North America ,Female ,Viral disease ,business ,Primary screening - Abstract
Several studies suggest that HPV testing is more sensitive than cytology in primary cervical screening. These studies had different designs and were reported in different ways. Individual patient data were collected for all European and North American studies in which cytology was routinely performed and HPV testing was included as an additional parallel test. More than 60,000 women were included. The sensitivity and specificity of HPV testing were compared with routine cytology, both overall and for ages
- Published
- 2006
- Full Text
- View/download PDF
9. Letter to the editor: Functional characterization of naturally occurring mutants of human papillomavirus type 16 with large deletions in the non-coding region
- Author
-
Karl Ulrich Petry, F. Krätzer, K. Grassmann, and Thomas Iftner
- Subjects
Genetics ,Cancer Research ,Type (biology) ,Letter to the editor ,Oncology ,Mutant ,Coding region ,Human papillomavirus ,Biology - Published
- 1996
- Full Text
- View/download PDF
10. Promoter usage in the E7 ORF of HPV16 correlates with epithelial differentiation and is largely confined to low-grade genital neoplasia
- Author
-
Karl Ulrich Petry, Matthias Dürst, Catharina Hemström Nilsson, Achim Schneider, and Evi Bakos
- Subjects
Gene Expression Regulation, Viral ,Cancer Research ,Papillomavirus E7 Proteins ,viruses ,Transplantation, Heterologous ,Mice, Nude ,Uterine Cervical Neoplasms ,In situ hybridization ,Biology ,Cervical intraepithelial neoplasia ,Mice ,Transcription (biology) ,medicine ,Animals ,Humans ,Papillomaviridae ,In Situ Hybridization ,Subgenomic mRNA ,Messenger RNA ,Carcinoma ,Cell Differentiation ,Promoter ,Oncogene Proteins, Viral ,Uterine Cervical Dysplasia ,Vulvar intraepithelial neoplasia ,medicine.disease ,Virology ,Molecular biology ,Open reading frame ,Oncology ,Carcinoma, Squamous Cell ,RNA, Viral ,Female ,Neoplasm Transplantation - Abstract
Human papillomavirus type 16 (HPV16) transcription in HPV16-positive vulvar intraepithelial neoplasia (VIN), cervical intraepithelial neoplasia (CIN) and cervical carcinomas was analyzed using RNA-RNA in situ hybridization. Subgenomic probes were constructed which specifically detected individual spliced E6/E7 transcripts as well as transcripts initiated within the E7 open reading frame (ORF). In most biopsies, viral RNA was predominantly initiated in the E6 ORF at promoter P97 and contained the E6*1 splice. Three of 7 VIN, 13 of 37 CIN and 1 of 13 cervical carcinomas expressed significant amounts of mRNA that were initiated within the E7 ORF. Promoter activity in the E7 ORF correlated with epithelial differentiation and viral late gene (L1) expression. Our data therefore do not support the finding of Bohm et al. (1993) which suggested that the predominant transcript(s) in HPV16-associated high-grade neoplasms and genital carcinomas is initiated within the E7 ORF. Rather, our data suggest that the major HPV16 transcript in high-grade cervical neoplasms and carcinomas is initiated in the E6 ORF and encodes the E7 oncoprotein. © 1996 Wiley-Liss, Inc.
- Published
- 1996
- Full Text
- View/download PDF
11. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions
- Author
-
Thomas Gabrysiak, Michael Glaubitz, Eckehardt Kupsch, Henning Kühnle, Ingolf Schedel, Heinrich G. Köchel, Ulrike Bode, Karl Ulrich Petry, Stefan Niesert, and Danicla Scheffel
- Subjects
CD4-Positive T-Lymphocytes ,Cancer Research ,Cellular immunity ,Pathology ,medicine.medical_specialty ,medicine.medical_treatment ,Uterine Cervical Neoplasms ,Cervical intraepithelial neoplasia ,Malignancy ,Lesion ,Immunocompromised Host ,Leukocyte Count ,03 medical and health sciences ,0302 clinical medicine ,Immunopathology ,medicine ,Humans ,Papillomaviridae ,030304 developmental biology ,Immunosuppression Therapy ,Colposcopy ,0303 health sciences ,medicine.diagnostic_test ,business.industry ,Papillomavirus Infections ,Immunosuppression ,Uterine Cervical Dysplasia ,medicine.disease ,3. Good health ,Oncology ,Tumor progression ,030220 oncology & carcinogenesis ,DNA, Viral ,Female ,medicine.symptom ,business - Abstract
Most cases of low-grade cervical intraepithelial neoplasia (CIN) associated with oncogenic human papillomavirus (HPV) types regress spontaneously within years. Unknown co-factors seem to be necessary for a progression to malignancy. To determine the possible role of cellular immunodeficiency as such a co-factor in the genesis of genital neoplasia, 48 HIV-infected women and 52 allograft recipients were examined periodically during a 3-year period. Colposcopy, cytology and HPV-DNA typing (ViraType) were performed at each visit. Each cervical lesion was matched prospectively with 2 lesions from immunocompetent controls. In all, 29/100 patients suffered from cervical neoplasms, including 2 advanced cervical cancers and 9 CIN3 lesions. Correlation between grade of lesion and HPV DNA 16/18 was significant. Low-grade lesions among patients progressed more often than among controls and recurrent lesions after destructive treatment were seen more frequently among patients than among controls. All patients with CD4-lymphocyte counts of < 400/microliters or immunosuppression for more than 3 years suffered from progressive lesions. We conclude that malfunction of the cellular immune response following either HIV-induced depletion or iatrogenic inhibition of CD4-lymphocyte activation, enhances the progression of HPV-induced cervical lesions to malignancy.
- Published
- 1994
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.